The American Cancer Society estimates that more than 313,780 cases of prostate cancer will be diagnosed in the United States in 2025, resulting in approximately 35,770 deaths. Bone metastasis - a ...

Erleada plus ADT may provide limited benefits for mCSPC patients with fewer bone metastases, affecting PFS2 and OS outcomes. Baseline bone metastasis count could guide treatment optimization for mCSPC ...

Prostate cancer patients with metastatic disease and low-volume primary tumors appear to have a poor prognosis, according to ...

When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...

Increased urinary urgency Frequent nighttime awakenings to urinate A slow or weak urinary flow Blood in the urine or semen As prostate cancer progresses and spreads to other areas of the body, it may ...

May 4, 2010 (Barcelona, Spain) — Monthly infusions of the bisphosphonate zoledronic acid significantly reduce the risk for bone fractures in men with prostate cancer and malignant bone metastases, ...

How Does Xofigo Work for Prostate Cancer? Xofigo is a radioactive medicine that works by providing radiation to your bones. The active radiation ingredient in Xofigo acts like calcium and attaches ...

Bone is a common site for metastasis of solid cancers, but histological and molecular features of bone metastases are not well understood. In a new study published in Cell Genomics, researchers at ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.